Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX…
Who's behind the signal
Every informed buyer we can see on SUPN, across all three feeds.
Not a model pick — but on our radar.
SUPERNUS PHARMACEUTICALS isn't in the top-10 model right now, but 7 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
7
Investors
2
New positions
2
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
▲
A member of Congress bought
▼
A member sold
Return: High: Low:
Markers sit on the transaction date the member disclosed, snapped to the
nearest close on the chart. They are not the date the public found out — that
came later, and
the gap is its own page.
Every marker is listed by name in the table above.
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to SUPERNUS PHARMACEUTICALS
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell SUPERNUS PHARMACEUTICALS or any security.